LivaNova - Page title

Press Releases

Mar 30, 2020

LivaNova to Host Conference Call for First Quarter 2020 Results

LONDON --(BUSINESS WIRE)--Mar. 30, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first quarter 2020 results on Wednesday, April 29, 2020 at 1 p.m. London time ( 8 a.m. Eastern Daylight Time )....Read More
Mar 26, 2020

LivaNova Autonomic Regulation Therapy for Heart Failure Findings to be Presented at American College of Cardiology and World Congress of Cardiology Virtual Meeting

LONDON --(BUSINESS WIRE)--Mar. 26, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced two abstracts focused on implantable neuromodulation technology for patients with heart failure will be shared at this year’s American College of...Read More
Mar 09, 2020

LivaNova VNS Therapy System, Symmetry, Granted CE Mark for Difficult-to-Treat Depression

Two UK patients receive innovative VNS Therapy implantable device through new pathway LONDON --(BUSINESS WIRE)-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its Vagus Nerve Stimulation Therapy ® (VNS Therapy) System, Symmetry™, earned CE...Read More
Feb 26, 2020

LivaNova Enters Research Collaboration with Verily to Gain New Insights into Vagus Nerve Stimulation Impact on Difficult-to-Treat Depression

RECOVER sub-study will leverage Verily research tools to provide quantitative assessment measures of depressive episodes LONDON --(BUSINESS WIRE)--Feb. 26, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced a research collaboration with...Read More
Feb 26, 2020

LivaNova Reports Fourth Quarter and Full-Year 2019 Results

LONDON --(BUSINESS WIRE)--Feb. 26, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full-year ended December 31, 2019 . For the fourth quarter of 2019, worldwide sales were $287.6 million , a decrease of 3.2...Read More
Feb 25, 2020

LivaNova Receives FDA Clearance for 3T Heater-Cooler Device Modification

LONDON --(BUSINESS WIRE)--Feb. 25, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for a device modification to its 3T Heater-Cooler ® devices....Read More
Feb 19, 2020

New International Consensus Statement Proposes “Difficult-to-treat Depression” as a More Clinically Useful Definition than “Treatment-Resistant Depression”

LONDON --(BUSINESS WIRE)--Feb. 19, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, commends the recent international consensus statement published in the Journal of Affective Disorders for recommendations to identify, assess and manage depression for...Read More
Jan 28, 2020

LivaNova to Host Conference Call for Fourth Quarter and Full-Year 2019 Results

LONDON --(BUSINESS WIRE)--Jan. 28, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its fourth quarter and full-year 2019 results on Wednesday, Feb. 26, 2020 at 1 p.m. London time ( 8 a.m. Eastern Standard Time )....Read More